

Glossary

adherence to therapy—Taking medications as prescribed.

AIDS (acquired immunodeficiency syndrome)—A specific group of diseases or conditions that indicate severe suppression of the immune system related to infection with the human immunodeficiency virus (HIV).

AIDS case definition—A standard definition of the physical and laboratory findings that make up an AIDS case. In 1993, the AIDS case definition was expanded to include a broader range of diseases and conditions and the results of immunologic testing, such as CD4+ T-cell counts. Consequently, the number of AIDS cases appeared artificially high in 1993 as more cases were included under the new definition.

antibody—An infection-fighting protein molecule in blood that attaches to and neutralizes viruses.

clinical trials—Studies conducted among volunteer participants; clinical trials test the safety and efficacy of new drugs. *Controlled* means that some participants actually receive the drug being tested while others receive placebo (an inactive substance). *Randomized* means that assignment to a group is random. *Double-blind* means that neither participants nor researchers know until after the study is completed who was assigned to which group; that is, who received the drug being tested and who received placebo.

All new vaccines must pass 3 phases of clinical trials before they can be considered for regulatory licensure.

Phase I—Tests for safety and dosage.

Phase II—Larger scale tests for safety.

Phase III—Large-scale studies for efficacy. For HIV vaccines, these tests must be performed in thousands of individuals who are HIV-negative but at high risk for HIV.

Where Is Information Available?

efficacy—Effectiveness of a drug or product under ideal (experimental) conditions, as opposed to under average (real-world) conditions.

epidemic—The occurrence in a community or region of cases of an illness, specific health-related behavior, or other health-related events clearly in excess of normal expectancy.

HAART (highly active antiretroviral therapy)—HIV treatment regimens, consisting of combinations of drugs that have been shown to reduce the amount of HIV virus in a patient's blood.

HIV (human immunodeficiency virus)—The virus that causes AIDS. Not all people infected with HIV have AIDS, but all people with AIDS are infected with HIV.

HIV counseling, testing, and referral

counseling—An HIV-prevention intervention. The counseling approach used is critical to the success of HIV prevention efforts. A client-centered HIV prevention counseling model has been shown to be especially effective. This model focuses on helping clients identify HIV risk behaviors and commit to personalized steps to reduce their HIV-related risks.

testing—Laboratory determination of HIV status. Voluntary testing can be obtained in medical care settings such as doctors' offices, hospitals, managed care organizations, and public health clinics or can be performed using home-collection kits. HIV testing may be required as part of screening programs for military personnel, blood donors, correctional facility inmates, and insurance applicants.

anonymous testing—People who choose anonymous HIV testing are not required to provide their names; therefore, test results are not linked to any records with an identifying name (including the request for tests or test results).

confidential testing—People who choose confidential testing provide their names, and testing information is documented in their record.

referral—The process by which immediate client needs for medical, prevention, and social support services are assessed, prioritized, and addressed (in the context of HIV prevention counseling and testing).

incidence—The number of new events, such as HIV infections, over time (usually a year).

intervention—An action intended to modify an outcome. Examples of HIV prevention interventions include counseling, educational messages, and discussion groups intended to help reduce HIV transmission.

outreach—Extending services to a wider section of the population than are currently receiving the services.

preclinical trials—Laboratory and animal studies designed to test the mechanisms, safety, and efficacy of a drug or medical device before, if ever, testing it in people.

prevalence—The number of people affected by a condition, such as HIV infection, at a given point in time.

surveillance—An ongoing, systematic process of collecting, analyzing, interpreting, disseminating, and evaluating data. Surveillance data are used to track disease and provide information for action to protect the public health.

AIDS surveillance—AIDS diagnoses are reported to CDC from all US states and territories.

HIV surveillance—A total of 49 states have some form of HIV infection reporting. Currently, 33 US states and territories have confidential, name-based HIV reporting systems and forward this information to CDC. However, it is not possible to examine trends in HIV diagnoses in all 33 states because many have just recently begun HIV reporting. Therefore, most of the HIV trends reported in this document come from data from 25 states that have required HIV reporting since 1993 (longstanding HIV reporting).

vaccine—A preparation that stimulates the body's immune system to protect itself from an invading virus.

virus—A microorganism made of either DNA or RNA with a protein coat. Viruses invade healthy cells and then use those host cells to replicate, spreading disease or infection. HIV, the virus that causes AIDS, is particularly dangerous because it attacks the body's immune system cells.

zidovudine—One of the drugs used to treat AIDS. May be abbreviated as ZDV or AZT.

Resources

The CDC National Prevention Information Network (NPIN)
 Phone 1-800-458-5231 or 1-800-243-7012 (TTY) or go to
www.cdcnpin.org

The following CDC publications can be obtained through NPIN:

2002 National Center for HIV, STD & TB Prevention Program Review
 Also available at www.cdc.gov/nchstp/od/program%20review/2002%20prog%20rev%20book%20FINAL.htm

Compendium of HIV Prevention Interventions with Evidence of Effectiveness
 Also available at www.cdc.gov/hiv/pubs/hivcompendium/hivcompendium.htm

HIV Counseling and Testing in Publicly Funded Sites: Annual Report
 (all years)
 Also available at www.nchstp.cdc.gov/dhap/pubs.htm

HIV Prevention Strategic Plan Through 2005
 Also available at www.cdc.gov/nchstp/od/hiv_plan/default.htm

HIV/AIDS Surveillance Report (all issues)
 Also available at www.cdc.gov/hiv/stats/hasrlink.htm

Revised Guidelines for HIV Counseling, Testing, and Referral
MMWR 2001;50(RR-19):1–58.
 Also available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5019a1.htm

Revised Recommendations for HIV Screening of Pregnant Women
MMWR 2001;50(RR-19):59–86.
 Also available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5019a2.htm

Additional websites

www.cdc.gov
(all of CDC)

www.cdc.gov/nchstp/od/nchstp.html
(CDC's National Center for HIV, STD, & TB Prevention)

www.cdc.gov/hiv/dhap.htm
(CDC's Divisions of HIV/AIDS Prevention)

www.cdc.gov/mmwr
(listing of all *Morbidity and Mortality Weekly Reports* [MMWRs])

www.cdc.gov/mmwr/hiv_aids20.html
(compilation of 25 notable MMWR issues on HIV and AIDS since 1981)

Related articles

Blair JM. Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990–1999. *Journal of Acquired Immune Deficiency Syndromes* 2002;31:339–347.

Bureau of Justice. *HIV in Prisons*, 2000. Washington, DC: US Department of Justice, Office of Justice Programs. October 2002. Also available at www.ojp.usdoj.gov/bjs/pub/pdf/hivp00.pdf

CDC. Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. *MMWR* 2003;52:329–332. Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5215a1.htm

CDC. Approval of a new rapid test for HIV antibody. *MMWR* 2002;51:1051–1052. Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5146a5.htm

CDC. Diagnosis and reporting of HIV and AIDS in states with HIV/AIDS surveillance—United States, 1994-2000. *MMWR* 2002; 51:595–598.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5127a3.htm

CDC. First report of AIDS. *MMWR* 2001;50:429.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5021a1.htm

CDC. The global HIV and AIDS epidemic, 2001. *MMWR* 2001; 50:434–439.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5021a3.htm

CDC. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immune deficiency syndrome. *MMWR* 1999;48(No. RR-13):1-31.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/rr4813a1.htm

CDC. HIV and AIDS—United States, 1981–2000. *MMWR* 2001; 50:430–434.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5021a2.htm

CDC. HIV diagnoses among injection-drug users in states with HIV surveillance—25 states, 1994–2000. *MMWR* 2003;52:634–636.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5227a2.htm

CDC. *HIV Partner Counseling and Referral Services*. Guidance.

Atlanta, Georgia: US Department of Health and Human Services, CDC. December 1998.

Also available at www.cdc.gov/hiv/pubs/pcrs.htm

CDC. HIV incidence among young men who have sex with men—seven US cities, 1994–2000. *MMWR* 2001;50:440–444.

Where Is Information Available?

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5021a4.htm

CDC. Incorporating HIV prevention into the medical care of persons living with HIV: recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of America. *MMWR* 2003;52(RR-12): 1–24.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5212a1.htm

CDC. Pregnancy in perinatally HIV-infected adolescents and young adults—Puerto Rico, 2002. *MMWR* 2003; 52:149–151.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5208a1.htm

CDC. Update: AIDS—United States, 2000. *MMWR* 2002; 51:592–595.

Also available at www.cdc.gov/mmwr/preview/mmwrhtml/mm5127a2.htm

Fleming PL, et al. Estimated number of perinatal infections, US, 2000. Abstract presented at the XIV International AIDS Conference; Jul 7–12, 2002; Barcelona, Spain.

Fleming PL, et al. HIV prevalence in the United States, 2000. Abstract presented at the 9th Conference on Retroviruses and Opportunistic Infections; Feb 24–28, 2002; Seattle, Washington.

Hammett TM, et al. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. *American Journal of Public Health* 2002;92:1789–1794.

Janssen RS, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. *JAMA* 1998;280:42–48.

Janssen RS, et al. The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals. *American Journal of Public Health* 2001;91:1019–1024.

Jones TS, et al. Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. *Journal of the American Pharmaceutical Association* 2002;42(suppl 2).

Karon JM, et al. HIV in the United States at the turn of the century: an epidemic in transition. *American Journal of Public Health* 2001;91:1060–1068.

Lindgren ML, et al. Trends in perinatal transmission of HIV/AIDS in the United States. *Journal of the American Medical Association* 1999;282:531–538.

Nakashima AK, et al. History of incarceration in HIV/AIDS patients recently reported to state/local health departments in the United States. Abstract presented at the XIV International AIDS Conference; Jul 7–12, 2002; Barcelona, Spain.

Nakashima AK, et al. HIV/AIDS surveillance in the United States, 1981–2001. *Journal of Acquired Immune Deficiency Syndromes* 2003;32(suppl 1):S68–S85.

Peters V, et al. Missed opportunities for perinatal HIV prevention among HIV-exposed infants born 1996-2000, Pediatric Spectrum of HIV Disease Cohort. *Pediatrics* 2003;111:1186–1191.

Quan VM, et al. HIV incidence in the United States, 1978-1999. *Journal of Acquired Immune Deficiency Syndromes* 2002; 31:188–201.

UNAIDS. *AIDS epidemic update—December 2002*.
Available at www.unaids.org/html/pub/Topics/Epidemiology/Slides02/slide04_PLWHA2002_map_en_ppt.ppt